- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03334643
Fiber Mix and Glycemic Response
The Effect of a Dietary Fiber Mix on Glycemic Response in Human: a Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is some evidence for increased dietary fiber intake to positively impact on metabolic outcomes in patients with type 2 diabetes, potentially via modulating gut microbial composition and functions. We have developed a dietary fiber mix that is consisted of fiber of various physicochemical properties to maximize the fermentability of the supplement and thus its effects on the gut microbiota. Since the fiber mix also contains nutrients that will raise blood glucose levels, we need to characterize the glycemic response to the fiber mix itself, before we can use it in an upcoming trial to determine the effect of dietary fiber supplementation on the gut microbiota and glycemic control.
Enrolled participants will be assigned to a subject group based on their diagnosis of type 2 diabetes and fasting blood glucose concentrations. Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes will be assigned to the Prediabetes/Diabetes group. For the other participants, those with fasting blood glucose < 100 mg/dL will be assigned to the Non-Diabetes group, and those with fasting blood glucose > 100 mg/dL will be assigned to the Prediabetes/Diabetes group.
Participants will attend 8 food testing visits over 2 weeks. For each visit, participants will attend the research facility in the morning after an overnight fast. They will consume either white bread (with 50 g of available carbohydrates as a control food) or 60 g of the fiber mix (as a drink).
Postprandial glycemic response will be assessed by changes in blood glucose levels, to be monitored using a continuous glucose monitoring system (FreeStyle Pro). A sensor will be placed on the participant's arm and will stay on until the end of the study.
Participants will provide photos of all the food and drink and a brief description of what they have consumed throughout the 2-week study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Institute for Food, Nutrition & Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Aged between 18 and 65 years
- Understand and be able to follow written and oral instructions in English
- Provide written informed consent
Exclusion Criteria
- Receiving insulin for diabetes treatment
- Receiving injectable prescription medicine
- Self-reported allergy or intolerance to any ingredients in the test food
- Any conditions deemed by the investigators that would prevent participation in the study, e.g. participation in past or active clinical research that may interfere with study outcomes, at the discretion of the investigators
- Any conditions deemed by the investigators that would compromise the individual's ability to complete the study, e.g. serious psychiatric conditions, at the discretion of the investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Non-Diabetes
Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL.
They will consume white bread or fiber mix for multiple times over a span of 2 weeks.
Changes in blood glucose levels will be monitored.
|
Participants will test white bread or fiber mix over a span of 2 weeks.
During each testing block, each food will be tested twice over two consecutive days.
There are 4 testing blocks in total (one for white bread and three for fiber mix).
|
|
Experimental: Prediabetes/Diabetes
Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL.
They will consume white bread or fiber mix for multiple times over a span of 2 weeks.
Changes in blood glucose levels will be monitored.
|
Participants will test white bread or fiber mix over a span of 2 weeks.
During each testing block, each food will be tested twice over two consecutive days.
There are 4 testing blocks in total (one for white bread and three for fiber mix).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postprandial glycemic response
Time Frame: The system will measure circulating blood glucose concentrations every 15 min continuously over 14 days. The data collected immediately prior to and up to 3 h after consuming the test food will be used to assess postprandial glycemic response
|
Circulating blood glucose concentration will be measured using a continuous glucose monitoring system (FreeStyle Libre Pro, Abbott Diabetes Care)
|
The system will measure circulating blood glucose concentrations every 15 min continuously over 14 days. The data collected immediately prior to and up to 3 h after consuming the test food will be used to assess postprandial glycemic response
|
Collaborators and Investigators
Investigators
- Principal Investigator: Liping Zhao, PhD, Rutgers University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-074m
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes Mellitus
-
Bangladesh Medical UniversityEnrolling by invitationType2 Diabetes MellitusBangladesh
-
Chonticha KaewjohoUniversity of PhayaoCompletedType2 Diabetes Mellitus | Autonomic Nervous System ImbalanceThailand
-
Mathias Ried-LarsenCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
NYU Langone HealthNot yet recruitingType2 Diabetes MellitusUnited States
-
Mariam Emeel Haleem NaseemNot yet recruitingType2 Diabetes Mellitus | CKD Stage 1-4 | Diet Pattern Analysis
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
Dasman Diabetes InstituteKuwait Foundation for the Advancement of SciencesEnrolling by invitationBariatric Surgery Candidate | Type2 DiabetesKuwait
-
Andalas UniversityUniversiti Putra MalaysiaCompleted
-
Medstar Health Research InstituteCompletedType2 Diabetes Mellitus
-
The University of Texas at San AntonioAmerican Diabetes AssociationUnknownType2 Diabetes MellitusUnited States
Clinical Trials on Fiber mix
-
PepsiCo Global R&DRadicle Science Inc.RecruitingQuality of Life | Wellness | HealthUnited States
-
dsm-firmenich Switzerland AGRecruitingIBS (Irritable Bowel Syndrome)India
-
Société des Produits Nestlé (SPN)Great Ormond Street Hospital for Children NHS Foundation TrustCompleted
-
Stanford UniversityNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingPrebioticsUnited States
-
Center of Food and Fermentation TechnologiesCompleted
-
University of Texas Southwestern Medical CenterCompletedNon-Insulin-Dependent Diabetes Mellitus
-
Prollergy dba Ready Set FoodObvioHealthActive, not recruiting
-
Maastricht University Medical CenterCompletedOverweight and ObesityNetherlands
-
Steno Diabetes Center CopenhagenDSM Nutritional Products, Inc.CompletedType 1 Diabetes | Diabetic Kidney Disease | Albuminuria | NephropathyDenmark
-
Universidade de Passo FundoCompletedDietary Habits | Bowel Dysfunction